Santaris Plans Phase II Trial of miRNA-Targeting HCV Drug

The company has also decided to keep the drug in-house until it has collected data from a phase II study of hepatitis C-infected patients, at which point it will pursue partnerships.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.